| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating activities: | ||||||
Net loss | ||||||
-19,479 | -16,702 | - | - | - | - | - |
Net loss | ||||||
- | - | -12,838 | -18,838 | -516 | 23,109 | -64,583 |
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Acquired in-process research and development | ||||||
- | 5,691 | - | - | - | - | - |
Amortization of note discount and patents | ||||||
- | - | - | - | - | - | 2,667 |
Warrants issued as investment fees | ||||||
- | - | - | - | - | - | 759 |
Depreciation | ||||||
1,351 | 1,351 | 343 | 338 | 299 | 127 | 82 |
Stock-based compensation | ||||||
4,271 | 46 | 700 | 1,995 | 483 | 775 | 1,437 |
Amortization of note discount | ||||||
- | - | - | - | - | 0 | - |
Warrants issued to placement agents | ||||||
- | - | - | - | - | 0 | - |
Amortization of patents | ||||||
- | - | 31 | 31 | 31 | 31 | - |
Impairment charges | ||||||
- | - | 5,800 | 9,547 | - | - | - |
Deferred taxes | ||||||
- | - | -1,302 | -556 | -73 | - | - |
Charge for common stock issuance | ||||||
- | - | 519 | - | - | 0 | 3,000 |
Costs related to equity offerings | ||||||
- | - | - | 569 | -213 | - | - |
Non-cash interest expense | ||||||
918 | 1,013 | 22 | 193 | - | - | - |
Change in fair value of derivative liabilities | ||||||
- | - | -2,010 | - | - | - | - |
Change in fair value of derivative liability | ||||||
1,117 | 1,724 | - | 4,538 | 9,940 | 37,219 | -49,330 |
Loss on sale of assets (Note 6) | ||||||
-663 | -145 | - | - | - | - | - |
Amortization of premiums of available-for-sale securities | ||||||
- | 33 | - | - | - | - | - |
Gain on re-valuation of liquidated damages liability | ||||||
- | - | - | - | 120 | - | - |
Stock-based compensation - severance | ||||||
- | - | - | - | - | 1,161 | - |
Changes in operating assets and liabilities: | ||||||
Other non-cash adjustments, net | ||||||
918 | 1,013 | - | - | - | - | - |
Accounts receivable, net | ||||||
- | - | - | - | 25 | 92 | -15 |
Tax refund | ||||||
- | - | - | - | - | 0 | -618 |
Accounts payable and accrued liabilities | ||||||
-1,374 | 144 | -838 | 406 | -123 | -977 | 454 |
Accrued compensation | ||||||
-853 | - | - | - | - | - | - |
Deferred rent and lease liabilities, net | ||||||
310 | 287 | - | - | - | - | - |
Deferred revenue | ||||||
- | - | - | - | - | 0 | - |
Accrued compensation | ||||||
- | - | - | - | 172 | 555 | - |
Prepaid expenses and other current assets | ||||||
-348 | 337 | -381 | -247 | 182 | 42 | 149 |
Net cash used in operating activities | ||||||
-15,582 | -10,627 | -9,192 | -10,606 | - | - | - |
Interest on loan notes | ||||||
- | - | - | - | - | 0 | 233 |
Other | ||||||
- | - | - | - | - | 0 | -155 |
Net cash used in operating activities | ||||||
- | - | - | - | -9,781 | -12,572 | -6,292 |
Investing activities: | ||||||
Purchases of available-for-sale securities | ||||||
- | 3,392 | - | - | - | - | - |
Proceeds from sales and maturities of available-for-sale securities | ||||||
- | 13,016 | - | - | - | - | - |
Purchases of property and equipment | ||||||
224 | 875 | 58 | 279 | 210 | 1,202 | 102 |
Proceeds from sale of property and equipment | ||||||
93 | 65 | - | - | - | - | - |
Cash acquired in reverse merger transaction | ||||||
3,008 | - | - | - | - | - | - |
Net cash used in investing activities | ||||||
2,877 | 8,814 | -58 | -279 | - | - | - |
Net cash used in investing activities | ||||||
- | - | - | - | -210 | -1,202 | -102 |
Financing activities: | ||||||
Payment of deferred consideration for asset acquisition | ||||||
-1,000 | - | - | - | - | - | - |
Proceeds from sale of common stock, net of offering costs | ||||||
9,975 | - | - | - | - | - | 16,887 |
Costs of Series B redeemable convertible preferred stock conversion to common stock | ||||||
- | - | - | 173 | - | - | - |
Dividend payments | ||||||
- | - | - | 80 | - | - | - |
Proceeds from sale of common stock and related warrants, net of offering costs | ||||||
- | - | 9,353 | 7,566 | 12,384 | - | - |
Proceeds from exercises of warrants | ||||||
- | - | 130 | - | 396 | - | - |
Proceeds from stock issuance under employee stock purchase plan | ||||||
- | - | 3 | 13 | - | - | - |
Principal payments on note payable | ||||||
- | - | -815 | -100 | - | - | - |
Net cash provided by (used in) financing activities | ||||||
8,975 | - | 8,671 | 7,226 | - | - | - |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||
-3,730 | -1,813 | - | - | - | - | - |
Proceeds from December financing | ||||||
- | - | - | - | - | 0 | - |
Proceeds from Series B redeemable convertible preferred stock | ||||||
- | - | - | - | - | 0 | 7,000 |
Proceeds from convertible loan notes | ||||||
- | - | - | - | - | 0 | 2,000 |
Net cash provided by financing activities | ||||||
- | - | - | - | 12,780 | 0 | 25,887 |
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | -579 | -3,659 | 2,789 | -13,774 | 19,493 |
Supplemental schedule of non-cash investing and financing activities: | ||||||
Issuance of common stock in reverse merger transaction | ||||||
10,709 | - | - | - | - | - | - |
Conversion of deferred asset acquisition consideration upon reverse merger | ||||||
1,463 | - | - | - | - | - | - |
Property and equipment included in accounts payable | ||||||
36 | 113 | - | - | - | - | - |
Conversion of convertible loan notes and accrued interest to Series B Redeemable Convertible Preferred Stock | ||||||
- | - | - | - | - | 0 | - |
Accretion of Series B redeemable convertible preferred stock | ||||||
- | - | - | 1,858 | 10,278 | 1,285 | - |
Fair value of warrant liability upon issuance | ||||||
- | - | - | 4,745 | 4,210 | - | - |
Unpaid offering costs | ||||||
116 | - | - | - | - | - | - |
Offering costs included in accounts payable | ||||||
- | - | - | 69 | - | - | - |
Property and equipment included in accounts payable | ||||||
- | - | 39 | - | - | - | - |
Fair value of warrant liability upon issuance | ||||||
- | - | - | - | - | 1,595 | - |
Conversion of convertible loan notes and accrued interest to Series B redeemable convertible preferred stock | ||||||
- | - | - | - | - | - | 6,316 |
Accretion of Series B redeemable convertible preferred stock | ||||||
- | - | - | - | - | - | 618 |